See more : CA Healthcare Acquisition Corp. (CAHCW) Income Statement Analysis – Financial Results
Complete financial analysis of Rani Therapeutics Holdings, Inc. (RANI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rani Therapeutics Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Urbana Corporation (URB.TO) Income Statement Analysis – Financial Results
- Zodiac-JRD-MKJ Limited (ZODJRDMKJ.NS) Income Statement Analysis – Financial Results
- PT Bank BTPN Tbk (BTPNF) Income Statement Analysis – Financial Results
- Northern Uranium Corp. (NRUNF) Income Statement Analysis – Financial Results
- bpost NV/SA (BPOSF) Income Statement Analysis – Financial Results
Rani Therapeutics Holdings, Inc. (RANI)
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 2.72M | 462.00K | 979.00K |
| Cost of Revenue | 822.00K | 1.31M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -822.00K | -1.31M | 2.72M | 462.00K | 979.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 39.62M | 36.61M | 26.48M | 12.04M | 24.58M |
| General & Administrative | 26.48M | 26.84M | 27.83M | 4.96M | 3.47M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.48M | 26.84M | 27.83M | 4.96M | 3.47M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 66.10M | 63.45M | 54.32M | 17.01M | 28.04M |
| Cost & Expenses | 66.10M | 63.45M | 54.32M | 17.01M | 28.04M |
| Interest Income | 3.30M | 1.25M | 89.00K | 63.00K | 423.00K |
| Interest Expense | 5.09M | 1.07M | 466.00K | 124.00K | 10.00K |
| Depreciation & Amortization | 822.00K | 1.31M | 497.00K | 589.00K | 564.00K |
| EBITDA | -65.28M | -60.89M | -52.08M | -15.96M | -26.01M |
| EBITDA Ratio | 0.00% | 0.00% | -1,895.84% | -3,439.83% | -2,663.74% |
| Operating Income | -66.10M | -63.45M | -51.60M | -16.54M | -27.07M |
| Operating Income Ratio | 0.00% | 0.00% | -1,899.12% | -3,580.95% | -2,764.56% |
| Total Other Income/Expenses | -1.78M | 177.00K | -1.45M | -124.00K | 478.00K |
| Income Before Tax | -67.88M | -63.27M | -53.05M | -16.67M | -26.59M |
| Income Before Tax Ratio | 0.00% | 0.00% | -1,952.41% | -3,607.79% | -2,715.73% |
| Income Tax Expense | 0.00 | 70.00K | 41.00K | 35.00K | 10.00K |
| Net Income | -33.97M | -63.34M | -53.09M | -16.70M | -26.60M |
| Net Income Ratio | 0.00% | 0.00% | -1,953.92% | -3,615.37% | -2,716.75% |
| EPS | -1.33 | -2.66 | -2.69 | -0.85 | -1.35 |
| EPS Diluted | -1.33 | -2.66 | -2.69 | -0.85 | -1.35 |
| Weighted Avg Shares Out | 25.51M | 23.82M | 19.71M | 19.74M | 19.74M |
| Weighted Avg Shares Out (Dil) | 25.51M | 23.82M | 19.71M | 19.74M | 19.74M |
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants
Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit
Rani Therapeutics to Participate in September Investor Conferences
Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update
Rani Therapeutics to Participate in August Investor Conferences
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
Rani Therapeutics to Participate in May Investor Conferences
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
Source: https://incomestatements.info
Category: Stock Reports